Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tiziana Life Sciences: Expansion into new clinical indications - Proactive Research Analyst

By: News Direct
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

--News Direct--

Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a new research note on clinical-stage biopharmaceutical company Tiziana Life Sciences Ltd (NASDAQ: TLSA). Tiziana has disclosed plans to file INDs (Investigational New Drug applications) aiming to expand the clinical indications of its lead product, intranasal foralumab, into mild-to-moderate Alzheimer’s Disease (AD) and long COVID-19.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/tiziana-life-sciences-expansion-into-new-clinical-indications-proactive-research-analyst-254277864

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  250.38
-11.99 (-4.57%)
AAPL  348.22
+4.23 (1.23%)
AMD  507.93
-44.79 (-8.10%)
BAC  51.08
+0.30 (0.59%)
GOOG  320.76
-10.19 (-3.08%)
META  648.85
-48.67 (-6.98%)
MSFT  521.08
-11.87 (-2.23%)
NVDA  212.21
-9.76 (-4.40%)
ORCL  125.54
-3.59 (-2.78%)
TSLA  374.58
-11.89 (-3.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.